Straits Times Index
3,246.33 -13.70 (-0.42%) Nikkei
26,717.34 +547.04 (+2.09%) Hang Seng
23,550.08 -256.92 (-1.08%) FTSE 100
7,466.07 -88.24 (-1.17%) BTC-USD
37,721.00 +1,128.92 (+3.09%) CMC Crypto 200
863.83 +21.37 (+2.54%)
Humanigen, Inc. (HGEN)
After hours:
| Previous close | 2.2100 |
| Open | 2.2600 |
| Bid | 2.3700 x 2200 |
| Ask | 2.4400 x 1400 |
| Day's range | 2.1450 - 2.3800 |
| 52-week range | 2.1450 - 29.2000 |
| Volume | |
| Avg. volume | 2,049,549 |
| Market cap | 140.793M |
| Beta (5Y monthly) | -1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.2280 |
| Earnings date | 08 Mar 2022 - 14 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.13 |
- Business Wire
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
BURLINGAME, Calif., January 18, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication in the Journal of Medical Economics (https://www.tandfonline.com/doi/full/10.1080/13696998.2022.2030148) citing the clinical and associated health economic benefits of lenzilumab. The publication demonstrated, in all cases, lenzilumab plus SOC
- Business Wire
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
BURLINGAME, Calif., January 10, 2022--Humanigen, Inc. (Nasdaq:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ today outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma (rrNHL).
- Business Wire
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
BURLINGAME, Calif., January 05, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’, announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved. The study, sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, enrolled over 400 patients in the primary analysis population at approxim
